361 related articles for article (PubMed ID: 8648393)
1. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
[TBL] [Abstract][Full Text] [Related]
2. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
4. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
6. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
[TBL] [Abstract][Full Text] [Related]
7. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
8. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
[TBL] [Abstract][Full Text] [Related]
9. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
[TBL] [Abstract][Full Text] [Related]
10. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
13. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.
Tsurumi H; Kanemura N; Hara T; Kasahara S; Yamada T; Sawada M; Oyama M; Moriwaki H
J Cancer Res Clin Oncol; 2007 Aug; 133(8):547-53. PubMed ID: 17453240
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
[TBL] [Abstract][Full Text] [Related]
19. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
